HAVCR2 and melanoma: As anti-Tim-3 treatment alone has limited or no anti-tumor efficacy in the B16 melanoma model [66,67,68,69], these data suggest that Tim-3 blockade synergizes with DC vaccines to improve their anti-tumor efficacy.